Novel Rx
Dr. John Cush RheumNow
3 years 1 month ago
Biosimilar switching is due to costs, formulary, relocation. Study of 23 studies, 3657 pts found only observational data, no RCTs. Ref product to biosimilar usually RCTs; Biosimilar switches usually real world evidence w/ good efficacy & no new risks. https://t.co/odAYHdbVd1 https://t.co/BabkVYsMBL
Dr. John Cush RheumNow
3 years 1 month ago
Are you a fan of the RheumNow podcast? Please rate, like and review us wherever you get your podcast. We'd appreciate it!
Dr. John Cush RheumNow
3 years 1 month ago
Network metanalysis & review looked at Biologics & remission in Crohns disease (25 RCTs; 8720 pts). -Compared to PBO Rankings were #1) infliximab 5 mg/kg (RR=0.67), #2) risankizumab 600 mg, #3) upadacitinib 45 mg. RIZ was 1st in biologic-naïve pts https://t.co/JFTEpqSJ6c https://t.co/65vbZkLmpC
We've got a lot to discuss this week: psoriasis; fatigue; sleep; sural nerve biopsies; uveitis and SpA; diet and RA; tofacitinib and the ORAL surveillance study; what not to take with mycophenolate - and more. In what order should these items be discussed? This week the run down is based on popularity, measured by rheumatologist engagements on the website and social media.
Dr. John Cush RheumNow
3 years 1 month ago
150 PsA pts assessed preferences in chosing biologics (of most to less preferred):
1 Oral over SC or IV routes
2 Avoiding severe side effects
3 Resume normal activity
4 Avoid infections
5 Improve enthesitis & 6 psoriasis
7 remission
8 Joint pain https://t.co/kE3qtTWBhH https://t.co/KKcsQqEYKf
A population-based study from Ontario, Canada suggests an increased mortality risk in patients with giant cell arteritis (GCA), according to a recent report in Arthritis Care & Research.
A health administrative data study looked at 22,677 GCA patients (≥50 years of age) compared to an age matched population for mortality rates between 2000 and 2018. Standardized mortality ratios (SMRs) were estimated.
Dr. John Cush RheumNow
3 years 1 month ago
CARRA Registry study of Kids who D/C DMARDs or biologics but flared & restarted meds: the recapture rate was 55% overall (47% oligoarthritis, 69% systemic JIA. By 12 mos 67% of children achieved inactive dz - better odds w/ restarting biologics (OR 2.74) https://t.co/Psgtd0O2jO https://t.co/xsecVRJqOL
Dr. John Cush RheumNow
3 years 2 months ago
Study of 57 #RA pts. w/ ILD treated with abatacept. Lung progression in 46% before ABA. After median 27 mos of follow-up, ILD
- 72% improved or stabilized
- 23% worsened
- 5% died.
No significant change in FVC, DLCO
ILD worse assoc w/ DAS28, FVC DLCO https://t.co/kLa61ZS8dt https://t.co/7XhqxcHuCt
A small retrospective study suggests that patients with difficult to treat adult-onset Still's disease (AOSD) or sytemic juvenile idiopathic arthritis (sJIA) may respond well to JAK inhibitor (JAKi) agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN.
Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.
Dr. John Cush RheumNow
3 years 2 months ago
Biosimilar availability is slow coming in US (only RTX, Inflx), but by 2030 these rheumatologic biologics should be available as biosimilars:
- rituximab
- infliximab
- adalimumab
- etanercept
- golimumab
- abatacept
- tocilizumab
- ustekinumab
- denosumab
https://t.co/Jjy9xrk4PA https://t.co/4Ht7HSngHQ
The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).
This guideline builds on past ACR vaccination guidance, last published in 2021.
Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.
The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of non-radiographic axial spondyloarthritis (nr-AxSpA), extending the efficacy of UPA beyond classic ankylosing spondylitis.
Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.
Poster Hall